Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10191357rdf:typepubmed:Citationlld:pubmed
pubmed-article:10191357lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:10191357lifeskim:mentionsumls-concept:C0021585lld:lifeskim
pubmed-article:10191357lifeskim:mentionsumls-concept:C0017628lld:lifeskim
pubmed-article:10191357lifeskim:mentionsumls-concept:C0055363lld:lifeskim
pubmed-article:10191357lifeskim:mentionsumls-concept:C0056889lld:lifeskim
pubmed-article:10191357lifeskim:mentionsumls-concept:C0312418lld:lifeskim
pubmed-article:10191357lifeskim:mentionsumls-concept:C0036667lld:lifeskim
pubmed-article:10191357pubmed:issue3lld:pubmed
pubmed-article:10191357pubmed:dateCreated1999-6-1lld:pubmed
pubmed-article:10191357pubmed:abstractTextIncreasing evidence is now accumulating for the involvement of the cystic fibrosis transmembrane conductance regulator (CFTR) in the control of the outwardly rectifying chloride channel (ORCC). We have examined the sensitivity of ORCC to the sulfonylurea drug glibenclamide in Hi-5 (Trichoplusia ni) insect cells infected with recombinant baculovirus expressing either wild-type CFTR, DeltaF508-CFTR or E. coli beta galactosidase cDNA and in control cells either infected with virus alone or uninfected. Iodide efflux and single channel patch-clamp experiments confirmed that forskolin and 1-methyl-3-isobutyl xanthine (IBMX) or 7-methyl-1,3 dipropyl xanthine (DPMX) activate CFTR channels (unitary conductance: 9.1 +/- 1.6 pS) only in cells expressing CFTR. In contrast, we identified 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid (SITS)-sensitive ORCC in excised membrane patches in any of the cells studied, with similar conductance (22 +/- 2.5 pS at -80 mV; 55 +/- 4.1 pS at +80 mV) and properties. In the presence of 500 microm SITS, channel open probability (Po) of ORCC was reversibly reduced to 0.05 +/- 0.01 in CFTR-cells, to 0.07 +/- 0.02 in non-CFTR expressing cells and to 0.05 +/- 0.02 in DeltaF508-cells. In Hi-5 cells that did not express CFTR, glibenclamide failed to inhibit ORCC activity even at high concentrations (100 microm), whereas 500 microm SITS reversibly inhibited ORCC. In contrast in cells expressing CFTR or DeltaF508, glibenclamide dose dependently (IC50 = 17 microm, Hill coefficient 1.2) and reversibly inhibited ORCC. Cytoplasmic application of 100 microm glibenclamide reversibly reduced Po from 0.88 +/- 0.03 to 0.09 +/- 0.02 (wash: Po = 0.85 +/- 0.1) in CFTR cells and from 0.89 +/- 0.05 to 0.08 +/- 0.05 (wash: Po = 0.87 +/- 0.1) in DeltaF508 cells. In non-CFTR expressing cells, glibenclamide (100 microm) was without effect on Po (control: Po = 0. 89 +/- 0.09, glib.: Po = 0.86 +/- 0.02; wash: Po = 0.87 +/- 0.05). These data strongly suggest that the expression of CFTR confers glibenclamide sensitivity to the ORCC in Hi-5 cells.lld:pubmed
pubmed-article:10191357pubmed:languageenglld:pubmed
pubmed-article:10191357pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:citationSubsetIMlld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10191357pubmed:statusMEDLINElld:pubmed
pubmed-article:10191357pubmed:monthAprlld:pubmed
pubmed-article:10191357pubmed:issn0022-2631lld:pubmed
pubmed-article:10191357pubmed:authorpubmed-author:DevauchelleGGlld:pubmed
pubmed-article:10191357pubmed:authorpubmed-author:GolaMMlld:pubmed
pubmed-article:10191357pubmed:authorpubmed-author:CeruttiMMlld:pubmed
pubmed-article:10191357pubmed:authorpubmed-author:VerrierBBlld:pubmed
pubmed-article:10191357pubmed:authorpubmed-author:JulienMMlld:pubmed
pubmed-article:10191357pubmed:authorpubmed-author:BecqFFlld:pubmed
pubmed-article:10191357pubmed:authorpubmed-author:ChappeVVlld:pubmed
pubmed-article:10191357pubmed:issnTypePrintlld:pubmed
pubmed-article:10191357pubmed:day1lld:pubmed
pubmed-article:10191357pubmed:volume168lld:pubmed
pubmed-article:10191357pubmed:ownerNLMlld:pubmed
pubmed-article:10191357pubmed:authorsCompleteYlld:pubmed
pubmed-article:10191357pubmed:pagination229-39lld:pubmed
pubmed-article:10191357pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:meshHeadingpubmed-meshheading:10191357...lld:pubmed
pubmed-article:10191357pubmed:year1999lld:pubmed
pubmed-article:10191357pubmed:articleTitleCystic fibrosis transmembrane conductance regulator (CFTR) confers glibenclamide sensitivity to outwardly rectifying chloride channel (ORCC) in Hi-5 insect cells.lld:pubmed
pubmed-article:10191357pubmed:affiliationStation de Recherche de Pathologie Comparée INRA-CNRS 30180 Saint-Christol-lez-Alès F-30380, France.lld:pubmed
pubmed-article:10191357pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10191357pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10191357pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10191357lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10191357lld:pubmed